According to physicians in Scotland, “within three years” MDMA could be used to treat post-traumatic stress disorder (PTSD). Doctor and psychotherapist James Hawkins wants medics to join up for training to examine how MDMA may assist manage mental illnesses.
Hawkins, who treats patients with other psychedelics such as psilocybin believes that studies demonstrate MDMA is extremely cost-effective.
A study in Colorado showed that 76% of the 28 people involved in one clinical trial no longer suffered from PTSD 12 months after receiving treatment.
Another MDMA-assisted therapy research group in California found that 67% of treatment patients were cleared of PTSD following just 2 months of treatment, compared to the 32% of the placebo patients.
Dr Jake Hawthorn, a psychiatrist in southeast Scotland who is interested in utilising psychedelics to treat addiction, believes that conventional medicine is recognising the need for new methods of treatment.
He said: “MDMA is expected to be licensed in the US in 2023. I think we’ll follow within a couple of years, starting with psilocybin, maybe 2025.